Laurent Pharmaceuticals is a private biopharmaceutical company developing a clinical stage, orally-active drug candidate with potential to modulate the immuno-inflammatory response in Cystic Fibrosis patients.


Laurent Pharmaceuticals is a Montréal-based private biopharmaceutical company. Laurent has a clinical stage lead program focusing on LAU-7b, a once-a-day oral therapy addressing the persistent unresolved inflammation, a leading cause of lung tissue destruction in patients with Cystic Fibrosis (CF).The underlying technology was developed at the Research Institute of the McGill University Health Centre (RI-MUHC) and received an Orphan Drug Designation from the U.S. Food and Drug Administration.

LAU-7b is a novel and improved oral solid form of fenretinide, an investigational semi-synthetic retinoid. LAU-7b works by correcting the defective metabolism of arachidonic acid (AA) and docosahexanoic acid (DHA) and regulates inflammation via a pro-resolving mechanism, a new treatment paradigm with potential to resolve inflammation without inducing immunosuppression.